Bruker Corporation (NASDAQ:BRKR) saw its shares drop 8.75% in premarket trading Monday following the release of preliminary second-quarter figures that showed flat reported revenue and a decline in adjusted earnings. The company cited weak demand from the academic sector and softness in the U.S. biopharma market as key factors behind the results.
For the quarter ending June 30, 2025, Bruker announced preliminary revenue estimates ranging between $795 million and $798 million, roughly flat compared to the same period last year on a reported basis.
However, the company projects adjusted organic revenue declined by about 7% year-over-year, while revenue at constant exchange rates fell around 3%.
Adjusted earnings per share for Q2 2025 are expected to come in between $0.32 and $0.34, down roughly $0.19 from the prior year, factoring in a $0.06 negative impact from foreign currency fluctuations.
Reflecting on the results, a company executive commented, “Our second quarter performance reflects the challenging market conditions we’re experiencing in our key segments. The combination of academic spending constraints and biopharma market softness has created headwinds for our business.”
The sharp drop in Bruker’s stock price highlights investor worries about the firm’s near-term growth outlook amid ongoing sector pressures.
Bruker Corporation stock price
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.